This site is intended for healthcare professionals only

Patients to benefit from new lung cancer drug

Written by: | Published:

Patients to benefit from new lung cancer drug Patients to benefit from new lung cancer drug

A targeted drug for lung cancer will be made available to anyone who is eligible, the NHS has announced.

Sotorasib targets a genetic mutation, dubbed the ‘death star’, by medics and scientists, and has been proven during trials to prevent lung cancer from growing for 7 months.

NHS patients in England were the first in Europe to benefit from the drug in September thanks to an early access agreement made with the manufacturer.

Read more: Regulations making COVID-19 vaccination a condition of deployment to end

‘It is fantastic news for hundreds more patients and their families that they will now be able to receive this first of its kind treatment thanks to another deal struck by the NHS,’ said NHS chief executive Amanda Pritchard.

‘From life-changing drugs for cystic fibrosis to new treatments for sickle cell disease, this is the latest in a long list of deals we have struck to provide the latest cutting-edge therapies for patients.’

Read more: Nursing graduates will be hit by proposed loan repayment changes

Around one in eight lung cancer patients will have this lethal ‘death star’ mutation of the KRAS gene, so called because of its spherical appearance. This first-of-its-kind treatment has taken more than four decades to develop. The drug, which can be taken at home making it more convenient for patients, could also represent a major breakthrough in treatments for some of the world’s other deadliest cancers.

‘It is very exciting to see this ground-breaking treatment coming into use after 40 years of research on this important target, to directly help patients with lung cancer that carries this particular mutation,’ said NHS clinical director for cancer Peter Johnson.

‘The NHS is committed to saving more lives from cancer through better diagnosis and treatment, with molecular testing through our genomics programme increasingly important for selecting the best options for patients.’

What do you think? Leave a comment below or tweet your views to @IndyNurseMag

This material is protected by MA Healthcare Ltd copyright.
See Terms and Conditions.

Comments

Name
 
Email
 
Comments
 

Please view our Terms and Conditions before leaving a comment.

Change the CAPTCHA codeSpeak the CAPTCHA code
 

Read a free issue from Practice Nursing

Register to read a free issue from our sister publication, Practice Nursing.

Including articles on asthma, diabetes and more. Read your copy.

Newsletter

Sign up to the newsletter

About

Independent Nurse is the professional resource for primary care and community nurses, providing clinical articles for practice nurses and prescribers.

Newsletter

Subscribe to our newsletter and stay up to date with the latest nursing news.

Stay Connected

Stay social with Independent Nurse by following us on Twitter, liking us on Facebook or connecting on LinkedIn.

Archive

Need access to some of our older articles? You can view our archive, or alternatively contact us.

Contact Us

MA Healthcare Ltd.
St Jude's Church, Dulwich Road
London, SE24 0PB

Tel: +44 (0)20 7738 5454
Registered in England and Wales No. 01878373

Meet the team

Authors

Find out how to contribute to Independent Nurse here.